Table II.
Kinetics of TLR agonist induced macrophage differentiation
| Day 1 | Day 2 | Day 3 | % M1 | % M2 |
|---|---|---|---|---|
| - | - | - | 5 + 2 | 6 + 4 |
| R848 | R848 | R848 | 83 + 7 | 3 + 1 |
| PAM3 | PAM3 | PAM3 | 3 + 1 | 89 + 5 |
| PAM3 | PAM3 | R848 | 74 + 11 | 18 + 4 |
| R848 | R848 | PAM3 | 42 + 5 | 24 + 4 |
| R848 | R848 | - | 45 + 6 | 8 + 2 |
| PAM3 | PAM3 | - | 7 + 3 | 27 + 1 |
mMDSC were purified from normal donors as described in Fig 1 and stimulated in vitro with PAM3 (1 ug/ml) or R848 (3 ug/ml) for two days. The cells were then washed and re-stimulated with the same or different TLR agonist for a final day. Data show the mean percentage + SD of cells bearing an M1-like (25F9+/CD200R−) vs M2-like (25F9+/CD200R+) phenotype in independent studies of 3 donors. Results of treating cells for only two days is also shown.